Two studies address the role of hormonal shift across menstrual cycle in female dehumanization of other women. In Study 1, normally ovulating women (NOW) and women who use hormonal contraceptives (HCW) are compared in terms of how much they dehumanize other women and two other control targets (men and elderly people). In NOW, the level of dehumanization of other women, but not of men and elderl...

Carbohydrate antigen 125 (CA125) is a tumor-marker frequently associated with ovarian malignancies; however, benign gynecologic conditions (e.g. ovarian cysts) commonly cause a smaller increase in CA125 levels. This report describes an elderly Japanese woman with high CA125 levels and massive ascites caused by hypothyroidism. A 67-year-old woman presented herself with a weight gain of about 12 ...

O’Brien et al. (1) must be commended for evaluating the risk of thromboembolism among women with type 1 or 2 diabetes using hormonal contraception. Indeed, their study is robust and the drug safety issue too frequently overlooked. However, their conclusion that “the absolute risk of thromboembolism among women with type 1 or 2 diabetes using hormonal contraception is low” deserves comment as am...

Barrier methods such as condoms and diaphragms are the most commonly used forms of birth control among HIV positive women. Sterilization is the second most popular method and hormonal contraception is the third Hormonal contraceptives, when used correctly and consistently, are highly effective in preventing unintended pregnancy and are also useful for treating health conditions such as painful ...

Journal of Family Planning and Reproductive Health Care 2004: 30(3) Background It is estimated that 69% of women initiate breastfeeding in the UK.1 The number breastfeeding then falls and by 6 months postpartum only 21% of women continue.1 Exclusive breastfeeding for 6 months or more is promoted worldwide to achieve optimal infant and maternal health.2 In the UK it is difficult to ascertain the...

Genitourinary syndrome of menopause (GSM) causes significant symptomatic aggravation that affects the quality life (QoL). Vulvovaginal atrophy (VVA), hallmark GSM, is managed with topical non-hormonal therapy, including moisturizers and lubricants, estrogen application. Patients not responding/being unsatisfied previous local therapies are candidates for a noninvasive modality. Carbon dioxide (...